The cellular health screening market size is estimated to be USD 2,649.5 million in 2022 and is expected to witness a CAGR of 9.67% during the forecast period 2023-2033. Growing government focus on preventive healthcare, soaring geriatric population and resulting growth in the need for cellular health screening, surge in research activities, and increasing prevalence of chronic diseases are factors contributing to the market growth. Furthermore, widespread adoption of telomere performance programmes for leading a healthy life, increasing awareness initiatives by different organisations throughout the world and numerous companies are starting initiatives to encourage cervical and vaginal cancer screening is projected to support the market. However, issues related to transport of samples and varying cost of test kits by the market players is expected to hinder the growth.

Numerous companies are starting initiatives to encourage cervical and vaginal cancer screening is expected to fuel the market. For instance, according to an article on theguardian.com, a campaign to raise awareness of life-saving screening was started in England in February 2022. The Department of Health and Social Care started this initiative.

Increasing awareness initiatives by different organisations throughout the world is expected to propel the market growth. The growing demand for testing-based preventive healthcare products and services is mostly due to increasing awareness initiatives by different organisations throughout the world. Collaboration between groups like the CDC, the U.S. Preventive Services Task Force (USPSTF), the National Cervical Cancer Coalition, and the WHO is one of the major drivers that is projected to drive the market over the forecast period.

Segmentation

By Test Type

The market is categorized into multi-test panels and single-test panels. In 2022, the single-test panels segment accounted for the highest revenue share. Over the course of the forecast period, the telomere single test panel is anticipated to have the quickest growth among the cellular health screening tests for telomere, inflammation, oxidative stress, and heavy metals. This is attributed by numerous studies that link telomere length to a variety of molecular and cellular processes. The introduction of new testing tools for measuring telomere length also contributes to the growth. For instance, Genomic Vision launched TeloSizer in September 2021 to promote the use of telomeres for biomarker identification through their accurate and quantitative detection. The market for multi-test panels is expected to grow at the quickest rate during the projected period. The use of these panels for screening several biomarkers in a single run has provided a number of benefits, including increased diagnostic accuracy, control the costs in healthcare settings, and competence in diagnosis. These factors are predicted to make multi-test panels more popular in the future than single-use ones.

By Sample Type

The market is categorized into saliva, blood, urine, and serum. In the global market, the blood segment accounted for the largest revenue share in 2022 owing to frequent usage of blood samples by medical professionals and use of diagnostic kits for assessing various medical conditions, organ function, and risk factor analysis. The introduction of new diagnostic tools that use blood for detection and screening is also driving market expansion. For instance, Osler, a blood-testing company, is raising funds from investors prior of the major release of their diagnostic device. The new device seeks to provide affordable blood tests and will deliver results in 10 minutes. Urine sample will exhibit significant growth during the projected period due to the fact that it does not require technical people, urine collection is much quicker and patient-friendly as it is non-invasive. Additionally, studies have shown that urine screening is a reliable method for determining oxidative stress. For instance, researchers from Japan demonstrated in a study article released in July 2020 that the presence of pteridine derivatives in urine is connected to smoking and oxidative stress. The market expansion of urine sample type screening is thus anticipated to be fuelled by the rising testing of oxidative stress in the human body.

By Collection

The market is segmented into hospital, home, diagnostic labs, and office. In 2022, the hospital segment accounted for the largest revenue share owing to usage of diagnostic kits for both in-patients and outpatients for health screening. Additionally, the market is expanding due to the presence of medical professionals and the advice of diagnostic tests for disease diagnosis. It is projected that the availability of sample collecting locations, skilled personnel, and cutting-edge diagnostic methods in one location would further help to the expansion. The home segment is anticipated to increase at the fastest rate during the projected period. This is attributed to rising health consciousness and widespread use of self-sampling in key markets. Self-sampling has become popular because it is simple to use and doesn’t require for specialised equipment or qualified personnel. For instance, Lab Corp declared in April 2022 that it had begun offering home collection services for the company’s range of diagnostic and screening test offers.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cellular health screening market and is expected to maintain its dominance during the forecast period. This is attributed to the surge in healthcare spending, increasing healthcare awareness among individuals, and government funding for preventative healthcare. These trends all contribute to the region’s increasing Healthy Life Expectancy (HALE), soaring healthcare costs, and rising healthcare spending. Regional development is further aided by the existence of significant key players, the ease with which new technologies are adopted, and the high prevalence of infectious and chronic diseases among the population. Asia Pacific is anticipated to be the region with the quickest rate of growth over the course of the projected period. This is due to two factors, a population that is expanding and resulting in a larger patient pool and an increasing medical infrastructure spurred on by rising economies. The main driving forces in the Asia Pacific region are the higher test adoption and adult individuals’ greater awareness of their health. Additionally, government programmes for disease prevention and greater study on telomere for ageing are supporting regional growth.

Competitor Insights

Some of the key players operating in the cellular health screening market are Repeat Diagnostics, Inc., Genova Diagnostics, Cell Science Systems Corp., SpectraCell Laboratories, Quest Diagnostics, LabCorp Holdings, OPKO, Telomere Diagnostics, Life Length, Immundiagnostik AG, and DNA Labs.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

For instance, Genova Diagnostics and Rocky Mountain Analytical, a division of LifeLabs, joined in September 2020. The collaboration made Genova’s testing easily accessible to clinics and patients in Canada.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including test type, sample type, and collection from 2023 to 2033.

Report Scope:

Segmentation:  Cellular Health Screening Market Report 2022 – 2033

Test Type (Revenue, USD Million), 2022 – 2033

• Single-test Panels
• Multi-test Panels
  • Oxidative Stress Tests
  • Telomere Tests
  • Heavy Metals Tests
  • Inflammation Tests

Sample Type (Revenue, USD Million), 2022 – 2033

• Saliva
• Blood
• Urine
• Serum

Collection (Revenue, USD Million), 2022 – 2033

• Hospital
• Home
• Diagnostic Labs
• Office

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA